ANTI-COAGULANT THERAPY IN HOSPITALIZED PREGNANT WOMEN WITH COVID-19: A BRIEF REVIEW

Arash Eatemadi*, Mohini Abreo, Fatima Al Matroushi, Thuwaiba Al Baluki, Ahmed Al Za?abi and Amal Al Shaaili

ABSTRACT

As our knowledge about COVID-19 progresses, we know that COVID-19 has a clear thrombogenic effect. Moreover, as pregnancy is a prothrombotic state, the possibility of an increased risk of venous thromboembolism (VTE) in pregnant women with COVID‐19 has become an area of concern, and a number of international organizations have proposed recommendations for thromboprophylaxis in pregnant and postpartum women with COVID‐19. However, these recommendations are mainly based on expert opinion. In this brief review, we explain the pathophysiology of COVID-19- associated coagulopathy with focus on pregnancy related issues, leading to make clear recommendations about anti-coagulant therapy in pregnant women with COVID-19 during hospitalization and also after discharge.

Keywords: COVID-19, Pregnancy, Prothrombotic state, Venous thromboembolism (VTE), COVID-19-associated coagulopathy, Thromboprophylaxis.